BCRX at a glance
BIOCRYST PHARMACEUTICALS INC (BCRX, SEC CIK 882796) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as September 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), BIOCRYST PHARMACEUTICALS INC (BCRX) reported revenue of $874.8 million (up 94.1% from FY2024) and net income of $263.9 million. Diluted EPS was $1.21.
- As of June 30, 2026, 32 institutional investment managers tracked by SignalX reported holding BIOCRYST PHARMACEUTICALS INC (BCRX) shares worth $1.0 billion in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $874.8M
- +94.1% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 32 funds
- $1.0B · +1 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02 · Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Biopharmaceutical company focused on development and commercialization of pharmaceutical products, including rare disease treatments like ORLADEYO
- Strategic shift: Sale of European ORLADEYO business with a Global Brand and Support Agreement limiting sole control over European brand positioning
- Quantitative metric: 52-week stock price range $6.00 to $11.31 per share for fiscal year 2025
- Noteworthy risk factor: Increased reliance on AI and cybersecurity amid expanded employee base and remote work, introducing new regulatory and operational risks
Risk Factors
- FDA approval of ORLADEYO oral pellet for pediatric HAE patients aged 2 to <12 years in December 2025
- Revenues from European ORLADEYO business divested in October 2025 for $254.5M cash proceeds
- Operational dependency risk from divestiture of BioCryst Ireland holding European ORLADEYO assets and employees
- Competitive risk from ongoing clinical development of Navenibart showing sustained HAE attack suppression in long-term trial
- Potential revenue milestone up to $14.0M from Neopharmed Gentili contingent on European sales before December 2032
Management Discussion & Analysis
- Merger-related expenses expected to be substantial but no $ amounts given
- Key risks: economic instability affecting counterparties, Merger integration challenges, clinical trial uncertainties, regulatory approval delays, and rare disease market complexities impacting future results and capital needs
AI summary of the BCRX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Quarterly revenue $218.25M vs $163.35M YoY, up $54.9M
- ORLADEYO revenue $158.20M vs $156.84M YoY
- License and other revenue $60.05M vs $6.52M, including $55.7M Neopharmed recognition
- Neopharmed agreement: $70.0M upfront consideration, up to $275.0M milestones, 18%-30% royalties
- Birmingham Closure Plan: discovery programs discontinued, implementation substantially complete by end-2026
Risk Factors
- Sustained profitability risk: 2025 marked first annual U.S. GAAP net income, but profitability remains unproven
- Royalty obligations: ORLADEYO revenues subject to RPI and OMERS payments under Royalty Purchase Agreements
- Commercialization risk: profitability depends on patient and physician acceptance, reimbursement levels, and competition
- Execution risk: inaccurate capital-allocation forecasts could undermine operational and budget plans
AI summary of the BCRX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, announced August 5, 2026
- Press release covers financial results and recent corporate developments
Item 7.01: Regulation FD Disclosure
- Reg FD disclosure furnished as Exhibit 99.1, with substantive information contained in the attached exhibit
- Disclosure not deemed “filed” under Exchange Act Section 18, limiting associated liability exposure
Item 2.05: Costs Associated with Exit or Disposal Activities
- Discovery programs discontinued and Birmingham Discovery Center of Excellence facility slated for closure
- One-time employee termination and severance expenses estimated at $6.2–$7.5 million
Item 2.05: Costs Associated with Exit or Disposal Activities
- Internal discovery programs discontinued, with Birmingham, Alabama Discovery Center of Excellence slated for closure
- Strategic pivot toward strengthening the rare disease pipeline following scientific and strategic review
Item 7.01: Regulation FD Disclosure
- June 29, 2026 press release disclosed the Plan and broader business updates
- Pipeline updates included, making the release relevant to Biocryst’s development strategy and valuation
AI summaries of BCRX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for BCRX
Don't miss the next BCRX filing
- Alerts as it files. A push when BCRX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BCRX, by share count.
- Ask anything. An AI agent that reads every BCRX filing and answers with sources.
BCRX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| MILANO VINCENT | A | Aug 31, 2026 | 1,159 | $9.70 |
| Frank Steven | A | Aug 31, 2026 | 1,288 | $9.70 |
| Stonehouse Jon P | A | Aug 31, 2026 | 644 | $9.70 |
| McKee Amy E | A | Aug 31, 2026 | 644 | $9.70 |
| Milne Jill C. | A | Aug 31, 2026 | 1,288 | $9.70 |
| Galson Steven K | A | Jun 11, 2026 | 15,294 | - |
| Stonehouse Jon P | A | Jun 11, 2026 | 15,294 | - |
| HEGGIE THERESA | A | Jun 11, 2026 | 15,294 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $331.4M | $450.7M | $874.8M |
| Operating Income | -$103.7M | -$2.5M | $341.0M |
| Net Income | - | -$88.9M | $263.9M |
| Op. Margin | -31.3% | -0.6% | 39.0% |
| Net Margin | - | -19.7% | 30.2% |
| Balance Sheet | |||
| Total Assets | $517.0M | $490.4M | $514.2M |
| Equity | -$455.5M | -$475.9M | -$119.2M |
| ROE | - | 18.7% | -221.4% |
| Per Share | |||
| EPS | $-1.18 | $-0.43 | $1.21 |
| Cash Flow | |||
| Operating CF | -$95.1M | -$52.0M | $347.4M |
Source: XBRL data in BIOCRYST PHARMACEUTICALS INC (BCRX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BCRX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 32 | $1.01B |
| Q1 2026 | 31 | $829.2M |
| Q4 2025 | 26 | $615.6M |
| Q3 2025 | 27 | $625.1M |
| Q2 2025 | 27 | $777.8M |
| Q1 2025 | 23 | $399.0M |
| Q4 2024 | 20 | $314.0M |
| Q3 2024 | 16 | $160.2M |
- Millennium Management+3.21M (+1708%)
- State Street Corp+2.98M (+24%)
- Goldman Sachs Group+2.13M (+91%)
- AQR Capital Management+1.77M (+403%)
- Renaissance Technologies LLC+1.75M (+226%)
- JPMorgan Chase & Co−1.02M (-66%)
- Bank of America Corp−290.5K (-6%)
- Bridgewater Associates LP−147.0K (-23%)
- Vanguard Portfolio Management LLC−105.5K (-1%)
- Invesco Ltd−75.0K (-6%)
- Allstate+40.9K
- Citizens Financial Group+10.6K
- Hilltop Holdings Inc.−10.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 202 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
BCRX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Sep 2, 2026 | - | - | - |
| SC 13G | Aug 7, 2026 | - | - | |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 8-K | Jun 29, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 4 | May 15, 2026 | - | - | |
| SC 13G | May 12, 2026 | - | - | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
BCRX SEC filings: frequently asked questions
Which institutions hold BCRX stock?
As of June 30, 2026, the largest BIOCRYST PHARMACEUTICALS INC (BCRX) holders among the 13F filers tracked by SignalX were BlackRock ($238.9 million), State Street Corp ($151.9 million), Vanguard Capital Management LLC ($113.6 million), Vanguard Portfolio Management LLC ($111.4 million), Two Sigma Investments ($67.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was BCRX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), BIOCRYST PHARMACEUTICALS INC (BCRX) reported revenue of $874.8 million (up 94.1% from FY2024) and net income of $263.9 million. Diluted EPS was $1.21. The figures come from the XBRL data in the 10-K.
What are the main risks in BCRX's latest 10-K?
In the 10-K filed February 26, 2026, BIOCRYST PHARMACEUTICALS INC (BCRX) flagged: FDA approval of ORLADEYO oral pellet for pediatric HAE patients aged 2 to <12 years in December 2025. Revenues from European ORLADEYO business divested in October 2025 for $254.5M cash proceeds. (AI summary of the Risk Factors section.)
What did BCRX report in its latest 8-K?
BIOCRYST PHARMACEUTICALS INC (BCRX) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q2 2026 results for quarter ended June 30, 2026, announced August 5, 2026.
What are the latest BCRX SEC filings?
BIOCRYST PHARMACEUTICALS INC (BCRX) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on September 2, 2026.
What is BCRX's SEC CIK number?
BIOCRYST PHARMACEUTICALS INC (BCRX)'s SEC Central Index Key (CIK) is 882796. EDGAR lists every BCRX filing under that number.
Ask anything about BCRX
The research agent reads BCRX's filings, financials, insider trades and 13F holders, then answers with sources.